TELA Bio seeks reverse split to meet Nasdaq bid requirement
TELA Bio plans a reverse stock split to comply with Nasdaq’s bid price requirement, trimming outstanding shares while keeping each holder’s percentage ownership unchanged, except for fractional shares that would be paid in cash. With authorized common shares staying at 200,000,000, the authorized but unissued pool would grow. The split ratio is proposed between 1-for-5 and 1-for-15 after a $0.79 bid close.